Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

por Jara, Michele, Barker, Graham, Henney, Herbert R
Publicado 2013

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

por Jara, Michele, Sidovar, Matthew F, Henney, Herbert R
Publicado 2014

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study

por Samara, Emil, Winkle, Peter, Pardo, Patricia, Henney, Herbert R, Way, Susan L, Brown, Eppie, Lee, Angela, Blight, Andrew R
Publicado 2014

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

por Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R
Publicado 2015